Evans T R, Harper C L, Beveridge I G, Wastnage R, Mansi J L
Department of Medical Oncology, St. George's Hospital Medical School, London, U.K.
Eur J Cancer. 1995;31A(2):174-8. doi: 10.1016/0959-8049(94)00420-a.
Cisplatin is an effective antineoplastic agent, but can cause renal tubular damage leading to urinary magnesium wasting and hypomagnesaemia. Cisplatin and 5-fluorouracil, when used in combination, have synergistic antitumour activity in upper gastrointestinal malignancies, but it is unclear whether they have additive effects on renal magnesium loss. To determine the optimal regimen for magnesium supplementation in these patients, we have conducted a randomised trial of routine intravenous magnesium supplements compared with magnesium given on an 'as required' basis. 32 patients were randomised to receive magnesium intravenously in prehydration and posthydration fluids with cisplatin chemotherapy, or to receive magnesium only when the serum level was low. 5-fluorouracil was given as a continuous infusion. Serum magnesium was measured on admission for each cycle of chemotherapy and an interim measurement performed between each cycle. 28 patients were evaluable. All patients randomised to receive magnesium on an 'as required' basis had at least one episode of hypomagnesaemia. On subsequent admissions for chemotherapy (cycles 2 and 3), the mean serum magnesium level was significantly lower in these patients compared with patients who received magnesium routinely (P < 0.05). After omission of magnesium from the first cycle of cisplatin, magnesium supplements were necessary in 50% of subsequent cycles, usually by the second or third cycle. Moreover, there were several instances of symptomatic hypomagnesaemia requiring further intravenous supplements in mid-cycle. Patients treated with a combination of cisplatin and 5-fluorouracil should be given intravenous magnesium supplements with each cycle of cisplatin chemotherapy. Nevertheless, episodes of hypomagnesaemia still occur, and additional intravenous supplements may be required, highlighting the importance of measuring this electrolyte.
顺铂是一种有效的抗肿瘤药物,但可导致肾小管损伤,进而引起尿镁排泄增多和低镁血症。顺铂和5-氟尿嘧啶联合使用时,对上消化道恶性肿瘤具有协同抗肿瘤活性,但它们对肾脏镁流失是否具有累加效应尚不清楚。为了确定这些患者补充镁的最佳方案,我们进行了一项随机试验,比较常规静脉补充镁与按需补充镁的效果。32例患者被随机分为两组,一组在顺铂化疗的水化前液和水化后液中静脉补充镁,另一组仅在血清镁水平低时补充镁。5-氟尿嘧啶采用持续静脉输注。在每个化疗周期入院时测定血清镁,并在每个周期之间进行一次中期测定。28例患者可进行评估。所有随机接受按需补充镁的患者均至少发生过一次低镁血症。在随后的化疗入院(第2和第3周期)时,与常规补充镁的患者相比,这些患者的平均血清镁水平显著降低(P<0.05)。在顺铂的第一个周期不补充镁后,50%的后续周期需要补充镁,通常在第二个或第三个周期。此外,有几例患者在化疗周期中期出现有症状的低镁血症,需要进一步静脉补充镁。接受顺铂和5-氟尿嘧啶联合治疗的患者,在每个顺铂化疗周期都应静脉补充镁。然而,低镁血症仍会发生,可能需要额外的静脉补充,这突出了检测这种电解质的重要性。